-62 The subject relates to an isolated antibody that specifically binds to 025b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of 5 producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody. Fig. 6 100-=p=0.0006 80 p=0.001 60- -- 8D5-1G1O 40- 8D10-C8 12-m PBS 0 3 6 9 12 15 18 21 Days post challenge

The present inventors provides one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile-associated disease (CDAD) in a patient according to a dosage regimen comprising: (1) administering to the patient in an initial course of treatment 200 mg of the tiacumicin compound twice a day; (2) monitoring the efficacy of the initial course of treatment in the patient by means of monitoring changes of one or more indicators of CDI or CDAD; (3) assessing whether there is a positive change of the one or the more of the indicators; and (4) switching to an intermittent course of treatment by administering to the patient 200 mg of the tiacumicin compound every other day if the one or the more of the indicators of CDI or CDAD are positively changed. Further the invention provides the use of the tiacumicin compound to reduce recurrence in a patient suffering from CDI or CDAD.

Disclosed herein are methods and compositions that can be used to treat and diagnose parkinsonism, for example Parkinson's disease, and uses for the same.

This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.

The present embodiments provide for media useful for selection and enrichment of Salmonella species. In a particular embodiment, the medium is a minimal medium that includes fructose-asparagine as the sole nutrient source. The fructose-asparagine utilization pathway, particularly FraB, provides a highly selective drug target for inhibiting Salmonella enterica.

The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost-effective and affordable, especially for lower-middle income and low-income countries.

The present invention provides compositions for delivering an active agent to an animal, comprising an active agent, a first coating, a second coating and a third coating. The active agent is coated with the first coating, the first coating is coated with the second coating, and the second coating is coated with the third coating. The active agent is in contact with the first coating, not the second or third coating. The first coating separates the active agent from the second coating while the second coating separates the first and third coatings. The first, second and third coatings are different from each other. Also provided are methods for making and using the compositions.

The present invention is directed generally to chimeric proteins that can facilitate targeting of nanoparticulate carriers to antigen presenting cells, and to nanoparticulate carriers comprising these chimeric proteins. The invention is also directed to methods of internalising an antigen in an antigen presenting cell, and methods of eliciting an immune response to an antigen in a subject, using the nanoparticulate carriers comprising the chimeric proteins.

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.

The present invention relates to a vaccine composition containing an attenuated Salmonella mutant as an active ingredient for simultaneously preventing or treating porcine proliferative enteropathy and Salmonella. The present invention was confirmed to induce humoral and cell-mediated immune responses to antigens in a mouse vaccinated with a mixture of the attenuated Salmonella mutant, when the attenuated salmonella was transformed using a vector developed to increase secretion of Lawsonia intracellularis-derived OptA, Optb, FliC or Hly antigens. Therefore, the mutant according to the present invention is expected to be useful as a vaccine for simultaneously preventing or treating porcine proliferative enteropathy and Salmonella, which is safe, economical, and safely inoculated.

Disclosed are methods for lysis of cells, such as bacteria present in microbiomes, that combine three lysis steps— (1) heat, (2) detergent and (3) base— into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allows for simplified removal of detergent after lysis, and importantly, yields improved quantities of genomic DNA (gDNA) from difficult to lyse bacteria.

The present invention relates to a vaccine composition for preventing brucellosis using a non-pathogenic Salmonella strain in which the O-antigen in an LPS is deleted, which expresses major common antigens of Brucella. When attenuated Salmonella in which the O-antigen of LPS is deleted was transformed using a vector developed to increase secretion of Brucella abortus-derived BLS, Omp19, PrpA and SOD antigens, and a mouse was vaccinated with a mixture of the Salmonella mutant that has been transformed and challenge infected, the present invention was confirmed to effectively induce humoral and cell-mediated immune responses to antigens in the mouse and provide an excellent defensive effect. As a result, the mutant according to the present invention is expected to be useful as a preventative or a therapeutic vaccine for brucella or Salmonella which is safe, economical, and safely inoculated.

Disclosed are methods for lysis of cells, such as bacteria present in microbiomes, that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allows for simplified removal of detergent after lysis, and importantly, yields improved quantities of genomic DNA (gDNA) from difficult to lyse bacteria.

There is described a method for determining the presence or absence of Salmonella or Shigella or Campylobacter coli in a sample, said method comprising: (1) contacting a sample, said sample suspected of containing Salmonella or Shigella or Campylobacter coli, with (a) at least two Salmonella -specific amplification oligomers for amplifying a target region of a Salmonella target nucleic acid, wherein the at least two Salmonella -specific amplification oligomers comprise first and second oligomers respectively comprising target-hybridizing sequences substantially corresponding to the nucleotide sequences of: (i) SEQ ID NO:1 and SEQ ID NO:2; (ii) SEQ ID NO:4 and SEQ ID NO:5; (iii) SEQ ID NO:8 and SEQ ID NO:9; (iv) SEQ ID NO:12 and SEQ ID NO:13; (v) SEQ ID NO:16 and SEQ ID NO:17; or (vi) SEQ ID NO:18 and SEQ ID NO:2; or (b) at least two Shigella -specific amplification oligomers for amplifying a target region of a Shigella target nucleic acid, wherein the at least two Shigella -specific amplification oligomers comprise first and second oligomers respectively comprising target-hybridizing sequences substantially corresponding to the nucleotide sequences of: (i) SEQ ID NO:45 and SEQ ID NO:46; (ii) SEQ ID NO:20 and SEQ ID NO:21; (iii) SEQ ID NO:26 and SEQ ID NO:21; (iv) SEQ ID NO:20 and SEQ ID NO:28; (v) SEQ ID NO:30 and SEQ ID NO:31; (vi) SEQ ID NO:36 and SEQ ID NO:37; or (vii) SEQ ID NO:41 and SEQ ID NO:42; or (c) at least two Campylobacter coli -specific amplification oligomers f

A composition comprising a probiotic and a prebiotic material. The probiotic is selected from one or more of the bacteria Bifidobacterium animalis, Collinsella tanakaei, Lactobacillus reuteri, Anaerostipes, Lactobacillus crispatus, Pediococcus acidilactici, Lactobacillus pontis, Faecalibacterium prausnitzii, Coprococcus catus, Roseburia intestinalis, Anaerostipes butyraticus, Butyricicoccus, Lactobacillus johnsonii, Ruminococcus sp. The prebiotic is preferably substantially indigestible in the gastrointestinal system of a chicken and is an oligosaccharide or inulin. In one embodiment, the composition further comprises a nutrient food course, and may be a starter feed or grower feed. The composition is used in the treatment of enteric bacterial disease in poultry, such a s broiler chickens, wherein the disease is infection by one or more of Clostridium perfringens, Salmonella spp, pathogenic and toxigenic Escherichia coli (EPEC and ETEC).

本发明公开了种鸭沙门氏菌灭活疫苗的制备方法，具体步骤如下：从当地肉鸭养殖场内选取感染鸭沙门氏菌的肉鸭，分离出鸭沙门氏菌；将鸭沙门氏菌进行扩大培养，灭活，4℃保存备用；配制佐剂：佐剂由以下重量份数的原料组成：司盘‑80 0.8‑1.2份，吐温‑80 1.5‑2.5份，蜂胶 1.5‑2.5份，按重量配比称取司盘‑80、吐温‑80和蜂胶，混合均匀；将灭活的鸭沙门氏菌稀释至其浓度大于5×109 CFU/mL，再将佐剂加入到菌液中，混合均匀，即可得到灭活鸭沙门氏菌疫苗。本发明的提供的鸭沙门氏菌灭活疫苗针对性强，对当地流行的沙门氏菌菌株免疫效果好，制备工艺操作简单，成本较低，易于储存，适用于有实验室的规模性养殖场。

本发明涉及株马流产沙门氏菌（）SMXJ‑97 CGMCC No.9047，具有序列表1中的16S rRNA基因序列；该菌株分离自新疆地区流产病马,细菌呈直杆状，大小为0.7~1.6μm×2.0~5μm，革兰氏染色阴性。为需氧兼性厌氧型细菌，在普通培养基上就可以生长，生长温度从25℃到40℃，最适温度37℃，pH生长范围5～9，最适PH7.4～7.6。可以发酵甘露醇，分解赖氨酸，不分解尿素，不能利用色氨酸、丙二酸盐、水杨苷，山梨醇。该菌株可用于制备马流产沙门氏菌病灭活疫苗。由该菌株制备的疫苗针对性好，成本低，安全，保护效果好。

本发明公开了马流产沙门氏菌来源的鞭毛蛋白FliC的制备方法和其在马流产沙门氏菌病免疫中的可能应用。通过将马流产沙门氏菌来源的鞭毛蛋白FliC基因克隆并连接到原核表达载体pGEX‑4T‑2中，获得该蛋白的原核重组体,转化至工程菌BL‑21中并对该蛋白进行诱导表达及纯化，该蛋白具有序列表1中的氨基酸序列，纯化后的FliC重组蛋白免疫实验动物后具有良好的免疫原性，该FliC重组蛋白可克服灭活疫苗产生的抗体水平低和安全性不佳的缺点，可用于制备防治马副伤寒感染的亚单位疫苗和作为马属动物疫苗佐剂使用,具有良好的开发应用前景。

A biosensor system for the detection of target analytes that includes a living biological cell of a predetermined type; a signal-generating reporter associated with the living biological cell; a signal transduction pathway or other activator mechanism or means associated with the signal-generating reporter; a universal detector element associated with the activator mechanism; and an analyte binding element associated with the universal detector element, wherein the analyte binding element is specific to both the universal detector element and a target analyte.

Guanidine-functionalized perlite particles are provided. Nonwoven articles are also provided, including a fibrous porous matrix and guanidine-functionalized perlite particles enmeshed in the fibrous porous matrix. Laminated articles are additionally provided, including a first substrate and a second substrate sealed to the first substrate along at least a portion of a perimeter of the first substrate. The laminated article further includes guanidine-functionalized perlite particles disposed between the first substrate and the second substrate. Methods of detecting microorganisms or target cellular analytes in a fluid sample using guanidine-functionalized particles or laminated articles are also provided.

Methods for rapidly concentrating a food sample for efficient detection of bacteria are disclosed. A microfiltration approach followed by centrifugation was used to concentrate the cells with an enzyme (e.g., a protease) added at the beginning of the process to facilitate more efficient micro-filtering. The enzyme was found to have no significant effect on cell viability.

The invention relates to methods promoting the aggregation of Salmonella bacteria in the gut of subjects, thereby providing immune exclusion and limiting bacterial entry, therefore reducing mucosal and systemic infection.

This invention is directed to methods and compositions for sorting and/or determining microscopic organisms or cells. The methods and compositions are directed to the use of molecular probes to selectively stain the organisms or cells in combination with the use of binding partners to selectively immobilize the stained organisms or cells to a solid carrier. By combining the selectivity of both molecular probes and binding partners in an orthogonal method for staining and immobilization, these methods and compositions increase both the discriminating power of the assays and/or the certainty of the result obtained therefrom.

This invention relates to immunogenic compositions, particularly vaccine compositions, for use in providing protection against illness caused by bacterial infection with Shigella strains.

Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S.typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.